As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Zhejiang NHU is a manufacturer of nutritional supplements, fragrances, active pharmaceutical ingredients, and polymer materials. More than 60% of its revenue in 2016 came from exports.
Hunan Jingfeng primarily manufactures and supplies biomedicines. The company focuses on cardiovascular diseases and anti-cancer drugs. Some of its products have gained approval in the United States, the...
Hangzhou Tigermed Consulting is a contract research organization that offers full clinical trial services. The firm has clinical centers in South Korea, Hong Kong, Australia, Malaysia, and Singapore, with...
Hubei Jumpcan Pharmaceutical specializes in pediatric medicines, as well as treatments for respiratory and digestive systems.
Zhongzhu Holding has three lines of businesses: 1) manufactures pharmaceuticals with a focus on eye drops; 2) sale of radiation therapy devices for tumors; 3) residential real estate. Starting in 2016,...